Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

84.49USD
18 Jun 2019
Change (% chg)

$1.19 (+1.43%)
Prev Close
$83.30
Open
$83.59
Day's High
$84.67
Day's Low
$83.50
Volume
2,664,225
Avg. Vol
3,194,669
52-wk High
$84.67
52-wk Low
$59.81

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $217,531.70
Shares Outstanding(Mil.): 2,574.65
Dividend: 0.55
Yield (%): 2.60

Financials

  MRK.N Industry Sector
P/E (TTM): 25.52 31.89 36.81
EPS (TTM): 3.31 -- --
ROI: 13.08 12.41 12.05
ROE: 28.61 13.73 16.96

Walmart, Merck in blockchain collaboration with FDA

June 13 IBM Corp, Merck & Co, KPMG and Walmart Inc said on Thursday they will be a part of U.S. Food and Drug Administration's pilot program that will explore using blockchain to identify, track and trace prescription drugs.

Jun 13 2019

Merck's Keytruda wins FDA approval to treat head and neck cancer

Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Jun 11 2019

UPDATE 1-Merck's Keytruda wins FDA approval to treat head and neck cancer

June 11 Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Jun 11 2019

Merck's Keytruda wins FDA approval to treat head and neck cancer

June 11 Merck & Co Inc said on Tuesday its blockbuster cancer drug Keytruda won approval from the U.S. Food and Drug Administration to treat a type of head and neck cancer.

Jun 11 2019

Merck to buy Tilos Therapeutics for up to $773 million

Drugmaker Merck & Co Inc said on Monday it agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases.

Jun 10 2019

Merck to buy Tilos Therapeutics for up to $773 mln

June 10 Drugmaker Merck & Co Inc said on Monday it agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases.

Jun 10 2019

US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

* Facebook, Amazon, Alphabet tumble on fears of regulatory risks

Jun 03 2019

Merck wins U.S. FDA approval for expanded use of antibiotic

The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

Jun 03 2019

UPDATE 1-Merck wins U.S. FDA approval for expanded use of antibiotic

June 3 The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

Jun 03 2019

Merck wins U.S. FDA approval for expanded use of antibiotic

June 3 The U.S. Food and Drug Administration on Monday approved expanded use of Merck & Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older.

Jun 03 2019

Earnings vs. Estimates